Theravance Biopharma (TBPH) Capital Expenditures Growth (3y) (2016 - 2025)
Theravance Biopharma (TBPH) Capital Expenditures Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 16.27% |
| 10 | Theravance Biopharma | 866.36 Mn | 471.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68.90% |
| Dec 31, 2024 | -24.64% |
| Sep 30, 2024 | -75.65% |
| Jun 30, 2024 | -38.66% |
| Mar 31, 2024 | -62.79% |
| Dec 31, 2023 | -18.36% |
| Sep 30, 2023 | -78.28% |
| Jun 30, 2023 | -28.88% |
| Mar 31, 2023 | -0.56% |
| Dec 31, 2022 | -41.12% |
| Sep 30, 2022 | -39.94% |
| Jun 30, 2022 | -41.89% |
| Mar 31, 2022 | -41.04% |
| Dec 31, 2021 | -33.36% |
| Sep 30, 2021 | -17.86% |
| Jun 30, 2021 | -47.76% |
| Mar 31, 2021 | -13.93% |
| Dec 31, 2020 | 69.60% |
| Sep 30, 2020 | 35.39% |
| Jun 30, 2020 | 47.49% |